Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA act mut TSC2 del |
Therapy | Taselisib |
Indication/Tumor Type | estrogen-receptor positive breast cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA act mut TSC2 del | estrogen-receptor positive breast cancer | resistant | Taselisib | Preclinical - Cell culture | Actionable | In a preclinical study, PIK3CA-mutant, ESR1 (ER)-positive breast cancer cell lines with knockout of TSC2 were resistant to treatment with Taselisib (GDC-0032) in culture (PMID: 33685991). | 33685991 |
PubMed Id | Reference Title | Details |
---|---|---|
(33685991) | Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors. | Full reference... |